PURPOSE: Fat absorption may play a crucial role in colorectal carcinogenesis by determining intra-colonic exposure to potentially carcinogenic lipid metabolites. METHODS: We conducted a population-based case-control study that included 1163 cases and 1501 controls to examine whether individuals who carry genetic variants associated with lower lipid absorption have a higher risk of colorectal cancer. Using Taqman assay, we determined FABP2 alanine (A)/threonine (T) polymorphism at codon 54 in exon-2 and APOE isoforms. Multivariable odds ratios (OR) and 95% confidence intervals (CI) were calculated by unconditional logistic regression models, assuming FABP2 A54 and APO non-E4 as high risk alleles. RESULTS: We found no associations with either of the polymorphisms. The OR associated with FABP2 A54 homozygotes compared with the others was 1.01 (95% CI; 0.86-1.45) and that for non-ApoE4 carriers compared with carries was 0.95 (95% CI; 0.80-1.13). However, there was a statistically significant negative interaction between total fat intake and FABP2 AA genotypes (p=0.025), indicating that the risk of colorectal cancer associated with this polymorphism is higher in the subjects with lower fat intake. CONCLUSIONS: These results suggest that these SNPs may not be useful in predicting colorectal cancer risk in populations with high fat intake. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
PURPOSE: Fat absorption may play a crucial role in colorectal carcinogenesis by determining intra-colonic exposure to potentially carcinogeniclipid metabolites. METHODS: We conducted a population-based case-control study that included 1163 cases and 1501 controls to examine whether individuals who carry genetic variants associated with lower lipid absorption have a higher risk of colorectal cancer. Using Taqman assay, we determined FABP2alanine (A)/threonine (T) polymorphism at codon 54 in exon-2 and APOE isoforms. Multivariable odds ratios (OR) and 95% confidence intervals (CI) were calculated by unconditional logistic regression models, assuming FABP2 A54 and APO non-E4 as high risk alleles. RESULTS: We found no associations with either of the polymorphisms. The OR associated with FABP2 A54 homozygotes compared with the others was 1.01 (95% CI; 0.86-1.45) and that for non-ApoE4 carriers compared with carries was 0.95 (95% CI; 0.80-1.13). However, there was a statistically significant negative interaction between total fat intake and FABP2 AA genotypes (p=0.025), indicating that the risk of colorectal cancer associated with this polymorphism is higher in the subjects with lower fat intake. CONCLUSIONS: These results suggest that these SNPs may not be useful in predicting colorectal cancer risk in populations with high fat intake. Copyright (c) 2010 Elsevier Ltd. All rights reserved.
Authors: Martha L Slattery; Carol Sweeney; Maureen Murtaugh; Khe Ni Ma; John D Potter; Theodore R Levin; Wade Samowitz; Roger Wolff Journal: Carcinogenesis Date: 2005-04-07 Impact factor: 4.944
Authors: Rowan T Chlebowski; Jean Wactawski-Wende; Cheryl Ritenbaugh; F Allan Hubbell; Joao Ascensao; Rebecca J Rodabough; Carol A Rosenberg; Victoria M Taylor; Randall Harris; Chu Chen; Lucile L Adams-Campbell; Emily White Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: Shirley A A Beresford; Karen C Johnson; Cheryl Ritenbaugh; Norman L Lasser; Linda G Snetselaar; Henry R Black; Garnet L Anderson; Annlouise R Assaf; Tamsen Bassford; Deborah Bowen; Robert L Brunner; Robert G Brzyski; Bette Caan; Rowan T Chlebowski; Margery Gass; Rosanne C Harrigan; Jennifer Hays; David Heber; Gerardo Heiss; Susan L Hendrix; Barbara V Howard; Judith Hsia; F Allan Hubbell; Rebecca D Jackson; Jane Morley Kotchen; Lewis H Kuller; Andrea Z LaCroix; Dorothy S Lane; Robert D Langer; Cora E Lewis; JoAnn E Manson; Karen L Margolis; Yasmin Mossavar-Rahmani; Judith K Ockene; Linda M Parker; Michael G Perri; Lawrence Phillips; Ross L Prentice; John Robbins; Jacques E Rossouw; Gloria E Sarto; Marcia L Stefanick; Linda Van Horn; Mara Z Vitolins; Jean Wactawski-Wende; Robert B Wallace; Evelyn Whitlock Journal: JAMA Date: 2006-02-08 Impact factor: 56.272
Authors: L J Baier; J C Sacchettini; W C Knowler; J Eads; G Paolisso; P A Tataranni; H Mochizuki; P H Bennett; C Bogardus; M Prochazka Journal: J Clin Invest Date: 1995-03 Impact factor: 14.808
Authors: J Lopez-Miranda; J M Ordovas; P Mata; A H Lichtenstein; B Clevidence; J T Judd; E J Schaefer Journal: J Lipid Res Date: 1994-11 Impact factor: 5.922
Authors: Ikuko Kato; Annemarie Boleij; Guus A M Kortman; Rian Roelofs; Zora Djuric; Richard K Severson; Harold Tjalsma Journal: Nutr Cancer Date: 2013 Impact factor: 2.900